ReviewThrombosis journal2026
Incidence and associated factors of venous thromboembolism in patients with gastric cancer across treatment settings after diagnosis: a systematic review and meta-analysis.
Review in Thrombosis journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a major complication in patients with cancer. Although gastric cancer is recognized as a high-risk malignancy for VTE, existing evidence has mainly focused on perioperative settings. The burden of thrombotic events across broader treatment settings after diagnosis remains less well characterized. This study aimed to estimate the incidence of thrombotic events in patients with gastric cancer across treatment settings after diagnosis and to summarize reported associated factors.
methodsA systematic review and meta-analysis was conducted in accordance with PRISMA 2020 guidelines. PubMed, Embase, Web of Science, and the Cochrane Library were searched from inception to January 31, 2026. Studies reporting thrombotic event incidence and/or associated factors in patients with pathologically confirmed gastric cancer were included. Random-effects models were applied. Heterogeneity was assessed using the I² statistic. Sensitivity and exploratory subgroup analyses were performed where applicable.
resultsTen studies comprising 9,689 patients were included. In the primary analysis, the pooled incidence of thrombotic events across treatment settings after diagnosis was 9.0% (95% CI 6.1%–13.2%), with substantial heterogeneity (I² = 97.4%). Quantitative analyses of associated factors, including sex, body mass index ≥ 25 kg/m², peritoneal metastasis, lung metastasis, and bone metastasis, did not establish consistent and reproducible independent associations under random-effects models.
conclusionsThrombotic risk appears clinically relevant in patients with gastric cancer across treatment settings after diagnosis, beyond short-term perioperative settings. However, current evidence does not establish robust and reproducible predictors for direct clinical implementation. Further large-scale prospective studies are needed to improve risk estimation and support future validation of risk assessment approaches in this population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.